1. Home
  2. Browse
  3. HRA002070
HRA002070
   HRA002070.xlsx
Title:
Palbociclib-based High-throughput Combination Drug Screening Identifies Synergistic Therapeutic Options in HPV-negative Head and Neck Squamous Cell Carcinoma
Release date:
2022-03-08
Description:
Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC). Despite being an attractive target, CDK4/6 inhibition using palbociclib showed modest or conflicting results as monotherapy or in combination with platinum-based chemotherapy or cetuximab in HPVneg HNSCC. Thus, innovative agents to augment the efficacy of palbociclib in HPVneg HNSCC would be welcomed.This study provides insights into the systematic combinatory effects associated with CDK4/6 inhibition and supports further initiation of clinical trials using the palbociclib plus alpelisib combination in HPVneg HNSCC with PIK3CA alterations.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA008473
Study type:
Cell line related study
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC001179
DAC name:
NCRC9H
Contact person:
Zhou rong
Email:
rongzhou@shsmu.edu.cn
Description:
National Clinical Research Center for Oral Diseases (ninth hospital)
Individuals & samples
Files
Request Data
Submitter:   Zhang zhiyaun / zhiyuan.zhang@sh9hospital.org.cn
Organization:   Shanghai Jiaotong University School of Medicine
Submission date:   2022-02-28
Requests:   -